学术周报 · IF≥10 或专科旗舰刊

胃肠外科领域文献阅读汇编

2026年第47周 (2026-11-20) | PubMed (NLM) · DeepSeek 中英双语
数据来源: PubMed E-utilities · 影响因子筛选: IF≥10 或专科旗舰刊 · 完整摘要不截断
收录论文
6
临床研究
3
基础研究
3
IF≥20
0
IF 10-20
4
子领域
2
期刊种类
4
数据日期
2026-11-20

★本周 Top 10 高影响力文献

#论文期刊IF
1FAP-targeted molecular imaging of CAFs-mediated chemoresistance and reversal by JAK/STAT inhibition ...Cancer lettersIF 11.8
2Chronic stress drives gastric cancer cachexia via cGAS-STING/NLRP3 signaling through a feedforward C...Cancer lettersIF 11.8
3Spatially resolved SPP1 expression is a biomarker of chemoimmunotherapy efficacy in advanced gastric...Journal for immunotherapy of cancerIF 11.7
4Effectiveness of Bariatric Surgery and Incretin-based Therapies on Cardiovascular Outcomes in Patien...European journal of preventive cardiologyIF 10.0
5Metastable chromatin state defines incomplete-type intestinal metaplasia and underlies its high carc...Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer AssociationIF 6.1
6HER2-low gastric cancer as a biologically distinct subgroup: DDR pathway alterations, immune activat...Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer AssociationIF 6.1

Ŧ期刊分布统计

期刊篇数IF
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association2IF 6.1
Cancer letters2IF 11.8
Journal for immunotherapy of cancer1IF 11.7
European journal of preventive cardiology1IF 10.0

1胃癌 (5篇)

临床研究 (2篇)

Journal for immunotherapy of cancer IF 11.7 2026-11-18 PMID: 43051942
Programmed death-ligand 1 (PD-L1) expression incompletely captures the tumor and immune contexture in gastric cancer, and clinical benefit within PD-L1 expression strata is heterogeneous. To explore additional chemoimmunotherapy biomarkers, we leveraged spatially resolved transcriptome profiling in two advanced gastric cancer cohorts: 70 patients from a completed phase II chemoimmunotherapy trial and 137 patients from an independent real-world immunotherapy cohort. In total, 1,337 tumor and immune areas of illumination were profiled from 794 regions of interest. In the trial cohort, SPP1, CXCL8, and IL1B, genes previously linked to tumor-promoting macrophage programs and immunotherapy resistance, were significantly downregulated within the tumor compartment in patients with durable clinical benefit (DCB) relative to those with no clinical benefit (NCB). In parallel, higher tumor-compartment SPP1 expression was significantly associated with inferior overall survival in the real-world cohort. Notably, these associations were weaker or absent in the immune compartment. Plasma proteomics suggested lower circulating SPP1 levels in patients with DCB than in those with NCB in the trial cohort. Collectively, these findings build on our prior work and nominate SPP1 expression as a spatially resolved correlate of chemoimmunotherapy efficacy.
中文摘要:程序性死亡配体1(PD-L1)表达未能完全反映胃癌的肿瘤和免疫微环境,且在PD-L1表达分层中临床获益存在异质性。为探索额外的化疗免疫治疗生物标志物,我们利用空间分辨转录组分析技术对两个晚期胃癌队列进行了研究:一个包含70名患者的已完成II期化疗免疫治疗试验队列和一个包含137名患者的独立真实世界免疫治疗队列。总共分析了来自794个感兴趣区域的1,337个肿瘤和免疫区域的光照数据。在试验队列中,与无临床获益(NCB)患者相比,具有持久临床获益(DCB)的患者肿瘤区内的SPP1、CXCL8和IL1B基因显著下调,这些基因此前被认为与促肿瘤巨噬细胞程序和免疫治疗耐药有关。与此同时,在真实世界队列中,较高的肿瘤区SPP1表达与较差的总生存期显著相关。值得注意的是,这些关联在免疫区较弱或不存在。血浆蛋白质组学结果表明,试验队列中DCB患者的循环SPP1水平低于NCB患者。综上所述,这些发现基于我们之前的工作,并将SPP1表达确定为化疗免疫治疗疗效的空间分辨相关性标志物。
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association IF 6.1 2026-11-13 PMID: 43024131
HER2-targeted therapy has been established as a key treatment strategy in gastric cancer. However, the genomic and immunologic characteristics of HER2-low advanced GC remain poorly understood. We investigated the molecular landscape and clinical significance of this emerging subgroup. We retrospectively analyzed 1067 advanced GC patients who underwent HER2 testing and targeted next-generation sequencing at Samsung Medical Center between October 2019 and March 2025. Patients were classified as HER2-negative (IHC 0), HER2-low (IHC 1+ or IHC 2+/ISH -), or HER2-positive (IHC 2+/ISH+ or IHC 3 +). Genomic alterations, key biomarkers (PD-L1, MSI, EBV, CLDN18.2), and overall survival by first-line treatment modality were compared across subgroups. Among 1067 patients, 805 (75.4%) were HER2-negative, 157 (14.7%) HER2-low, and 105 (9.8%) HER2-positive. HER2-low tumors showed the highest PD-L1 positivity (CPS ≥ 5: 60.1%) and MSI-H frequency (7.0%), with the lowest proportion of all-biomarker-negative patients. ERBB2 copy number followed a stepwise increase across three HER2 subgroups. HER2-low tumors were enriched for DNA damage repair (DDR)-related alterations, including BARD1 and SLX4, and showed more frequent PI3K/AKT pathway alterations compared to HER2-positive tumors. HER2-low status showed no significant association with overall survival in the chemotherapy-only cohort, whereas a non-significant overall survival difference was observed in the chemotherapy plus immune checkpoint inhibitor (Chemo+IO) cohort (20.0 vs. 16.9 months; HR 0.83; p = 0.157). HER2-low advanced GC appears to represent a biologically distinct subgroup characterized by DDR gene enrichment, PI3K/AKT pathway alterations, and an immune-active biomarker profile.
中文摘要:HER2靶向治疗已成为胃癌的关键治疗策略,然而HER2低表达晚期胃癌的基因组和免疫学特征仍不清楚。本研究旨在探讨这一新兴亚群的分子图谱及临床意义。我们回顾性分析了2019年10月至2025年3月在三星医疗中心接受HER2检测和靶向二代测序的1067例晚期胃癌患者。根据检测结果将患者分为HER2阴性(IHC 0)、HER2低表达(IHC 1+或IHC 2+/ISH阴性)和HER2阳性(IHC 2+/ISH阳性或IHC 3+)三组,并比较了各亚组的基因组改变、关键生物标志物(PD-L1、MSI、EBV、CLDN18.2)以及一线治疗模式的总生存期。在1067例患者中,HER2阴性者805例(75.4%),HER2低表达者157例(14.7%),HER2阳性者105例(9.8%)。HER2低表达肿瘤表现出最高的PD-L1阳性率(CPS≥5:60.1%)和MSI-H频率(7.0%),且所有生物标志物均为阴性的患者比例最低。ERBB2拷贝数在三组HER2亚型中呈阶梯式增加。与HER2阳性肿瘤相比,HER2低表达肿瘤富含DNA损伤修复(DDR)相关改变,包括BARD1和SLX4,且PI3K/AKT通路改变更为频繁。在仅接受化疗的队列中,HER2低表达状态与总生存期无显著关联;而在化疗联合免疫检查点抑制剂(Chemo+IO)队列中,观察到总生存期的差异无统计学意义(20.0个月 vs 16.9个月;HR 0.83;p=0.157)。HER2低表达晚期胃癌似乎代表了一个生物学上独特的亚群,其特征为DDR基因富集、PI3K/AKT通路改变以及免疫活跃的生物标志物谱。

基础研究 (3篇)

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association IF 6.1 2026-11-18 PMID: 43050001
Incomplete-type intestinal metaplasia (iIM) has both gastric and intestinal mucin phenotypes, often persists even after Helicobacter pylori eradication, and has a particularly high risk of gastric cancer. However, the molecular basis remains unclear. snRNA-seq and scATAC-seq were performed on normal human gastric tissue without HP infection, HP-infected gastric tissue without and with IM, and small intestinal mucosa. Mouse gastric mucosa with spasmolytic polypeptide-expressing metaplasia (SPEM), mucous neck cell-mimicking metaplasia from chief cells, was also analyzed. snRNA-seq of IM cells showed a distinct cluster of iIM cells with hybrid expression of gastric and small intestinal genes. The iIM cells, but not complete-type IM (cIM cells), displayed aberrant transcriptional activation of genes silent in both tissues, such as REG4 and BBOX1. By scATAC-seq analysis using biological replicate samples, iIM cells were consistently shown to have hybrid open chromatin at both gastric (SOX2) and small intestinal (CDX2) master regulators. The iIM cells showed extensive chromatin closure and an abrupt transition to cIM, supporting the relatively stable chromatin state. The iIM cells had aberrant opening of the posterior HOXA genes, presenting a feature of embryonic reprogramming. Analysis of mouse gastric spasmolytic polypeptide-expressing metaplasia (SPEM), pyloric metaplasia of body chief cells, also showed hybrid chromatin openings of SOX2 and CDX2, and aberrant closure of many chromatin regions. iIM cells exhibit a metastable chromatin state with features of embryonic reprogramming, suggesting increased stemness and a potential role in the acceleration of gastric carcinogenesis.
中文摘要:不完全型肠化生(iIM)兼具胃和肠黏膜黏蛋白表型,常在幽门螺杆菌根除后持续存在,且具有极高的胃癌风险。然而其分子基础尚不明确。本研究对无幽门螺杆菌感染的正常人类胃组织、有或无肠化生的幽门螺杆菌感染胃组织以及小肠黏膜进行了单细胞RNA测序(snRNA-seq)和单细胞ATAC测序(scATAC-seq)。同时分析了具有痉挛性多肽表达化生(SPEM)的小鼠胃黏膜,该模型模拟了主细胞来源的黏液颈细胞化生。iIM细胞的snRNA-seq结果显示了一个独特的iIM细胞簇,表现出胃和小肠基因的混合表达。与完全型肠化生(cIM)细胞不同,iIM细胞显示出REG4和BBOX1等在这两种组织中均沉默的基因的异常转录激活。通过生物重复样本进行的scATAC-seq分析一致表明,iIM细胞在胃主调节因子SOX2和小肠主调节因子CDX2处具有混合性开放染色质特征。iIM细胞表现出广泛的染色质闭合,并存在向cIM的突然转变,支持其相对稳定的染色质状态。iIM细胞还表现出后部HOXA基因的异常开放,呈现出胚胎重编程的特征。对小鼠胃SPEM和幽门螺杆菌感染的主细胞化生的分析也显示了SOX2和CDX2的混合染色质开放以及许多染色质区域的异常闭合。iIM细胞表现出具有胚胎重编程特征的亚稳态染色质状态,提示其干性增加并在加速胃癌发生中可能发挥作用。
Cancer letters IF 11.8 2026-11-16 PMID: 43039102
Chemotherapy resistance remains a major obstacle in the clinical management of gastric cancer (GC), driven largely by cancer-associated fibroblasts (CAFs). CAFs activate the JAK/STAT signaling pathway in GC cells, promoting proliferation, migration, and resistance to 5-fluorouracil (5-FU). Fibroblast activation protein (FAP), highly expressed on CAFs but minimally in normal tissues, is an attractive target for molecular imaging. Here, we developed FAPtp-ICG, a near-infrared fluorescent probe comprising an FAP-targeting peptide conjugated to indocyanine green (ICG), for noninvasive visualization of FAP expression. We established CAFs-conditioned GC models with graded chemoresistance, in which FAP-associated fluorescence and FAP expression were positively associated with the degree of CAFs-mediated 5-FU resistance in the experimental models. FAPtp-ICG enabled noninvasive fluorescence imaging of FAP-associated stromal changes, allowing longitudinal assessment of treatment-associated changes related to CAFs-mediated drug resistance. Mechanistically, combination therapy with 5-FU and ruxolitinib (RUX) suppressed JAK/STAT signaling, alleviated chemoresistance, inhibited tumor growth, and restored drug sensitivity. Multi-omics profiling further revealed that RUX treatment was associated with transcriptomic and proteomic alterations in the tumor microenvironment, attenuating inflammatory signaling, immune cell recruitment, and extracellular matrix remodeling. By integrating a FAP-targeted optical probe with therapeutic JAK/STAT inhibition, this work demonstrates a theranostic strategy for assessing and overcoming CAFs-mediated chemoresistance in GC, supporting the potential utility of FAP-targeted imaging for longitudinal assessment of treatment-associated stromal changes.
中文摘要:化疗耐药仍是胃癌临床管理的主要障碍,主要由癌症相关成纤维细胞驱动。癌症相关成纤维细胞激活胃癌细胞中的JAK/STAT信号通路,促进细胞增殖、迁移及对5-氟尿嘧啶的耐药性。成纤维细胞活化蛋白在癌症相关成纤维细胞上高表达而在正常组织中表达极少,是分子成像的理想靶点。本研究开发了FAPtp-ICG近红外荧光探针,该探针由靶向成纤维细胞活化蛋白的肽与吲哚菁绿偶联而成,用于无创可视化成纤维细胞活化蛋白的表达。我们建立了具有分级化疗耐药性的癌症相关成纤维细胞条件培养胃癌模型,实验结果显示成纤维细胞活化蛋白相关的荧光强度与表达量及癌症相关成纤维细胞介导的5-氟尿嘧啶耐药程度呈正相关。FAPtp-ICG实现了对成纤维细胞活化蛋白相关基质变化的无创荧光成像,允许纵向评估与治疗相关的癌症相关成纤维细胞介导的药物耐药变化。机制上,5-氟尿嘧啶与鲁索替尼联合治疗抑制了JAK/STAT信号通路,缓解了化疗耐药性,抑制了肿瘤生长并恢复了药物敏感性。多组学分析进一步揭示鲁索替尼治疗与肿瘤微环境的转录组和蛋白质组改变相关,减轻了炎症信号、免疫细胞募集及细胞外基质重塑。通过将靶向成纤维细胞活化蛋白的光学探针与治疗性的JAK/STAT抑制相结合,本研究展示了一种评估和克服胃癌中癌症相关成纤维细胞介导的化疗耐药的诊疗策略,支持了靶向成纤维细胞活化蛋白成像在纵向评估治疗相关基质变化中的潜在应用价值。
Cancer letters IF 11.8 2026-11-16 PMID: 43039101
Cancer cachexia is a multifactorial metabolic syndrome driven by advanced malignancies and is closely linked to poor treatment tolerance and unfavorable prognosis. The neural-tumor-immune crosstalk within the tumor microenvironment is increasingly recognized as a key determinant of cachexia progression. Here, we show that gastric cancer (GC) patients with chronic stress (CS) exhibit poor outcomes that are closely associated with advanced N stage, perineural invasion, and cachexia. In vivo, CS accelerates GC growth and induces cachectic phenotypes, including gastrocnemius loosening, myofiber atrophy, and epididymal white adipose atrophy with browning. Mechanistically, CS enhances neutrophil extracellular traps (NETs) formation and promotes sustained release of NETs-derived DNA, which drives both tumor progression and systemic metabolic wasting. NETs-DNA acts as a damage-associated molecular pattern (DAMP) that persistently activates the cGAS-STING/NLRP3 inflammasome signaling axis in macrophages in a time-dependent manner, leading to amplified inflammatory responses that promote myocyte atrophy and impair lipid droplet formation. In parallel, CS strengthens neuro-tumor communication; nociceptive neurons sustain NETs formation via a feedforward CGRP-NGF signaling loop, whereas gastric vagotomy attenuates CS-induced NETs formation and consequently suppresses both tumor progression and cachexia. Importantly, combined inhibition of the CGRP/RAMP1 axis and the cGAS-STING/NLRP3 pathway produces synergistic suppression of GC growth and cachectic phenotypes. Collectively, these findings identify a stress-neuro-immune circuit that drives GC progression and cachexia, and highlight the CGRP/RAMP1 and cGAS-STING/NLRP3 axes as potential therapeutic targets.
中文摘要:癌症恶病质是一种由晚期恶性肿瘤驱动的多因素代谢综合征,与耐受性差和不良预后密切相关。肿瘤微环境中的神经-肿瘤-免疫串扰日益被视为恶病质进展的关键决定因素。本研究显示,患有慢性应激的胃癌患者预后较差,这与N分期较晚、神经周围浸润和恶病质密切相关。在体内实验中,慢性应激加速了胃癌生长并诱导恶病质表型,包括腓肠肌松弛、肌纤维萎缩以及附睾白色脂肪组织褐变性萎缩。机制上,慢性应激增强了中性粒细胞胞外诱捕网(NETs)的形成并促进NETs来源DNA的持续释放,从而驱动肿瘤进展和全身代谢消耗。NETs-DNA作为损伤相关分子模式,以时间依赖性方式持续激活巨噬细胞中的cGAS-STING/NLRP3炎症小体信号轴,导致炎症反应放大,进而促进肌细胞萎缩并损害脂滴形成。同时,慢性应激加强了神经-肿瘤通讯;伤害性神经元通过正向CGRP-NGF信号环路维持NETs形成,而胃迷走神经切断术可减弱慢性应激诱导的NETs形成,从而抑制肿瘤进展和恶病质。重要的是,联合抑制CGRP/RAMP1轴和cGAS-STING/NLRP3通路可协同抑制胃癌生长和恶病质表型。综上所述,这些发现确定了一个驱动胃癌进展和恶病质的应激-神经-免疫回路,并突出了CGRP/RAMP1和cGAS-STING/NLRP3轴作为潜在治疗靶点的价值。

2减重/代谢手术 (1篇)

临床研究 (1篇)

European journal of preventive cardiology IF 10.0 2026-11-17 PMID: 43043854
Bariatric surgery and pharmacological weight-loss therapies improve cardiometabolic risk factors. However, direct head-to-head comparisons assessing their impact on cardiovascular outcomes remain limited. We performed an exploratory meta-analysis to compare bariatric surgery and pharmacological weight-loss therapies on major clinical outcomes in adults with obesity. A systematic literature search using PubMed and Scopus databases was conducted. Randomized and observational studies comparing bariatric surgery or incretin receptor agonists with controls were included in the analysis. The primary outcomes were all-cause mortality and MACE. A frequentist random-effects network meta-analysis was conducted across three nodes. A total of 40 studies, comprising more than 1.9 million patients, were included in the meta-analysis. Compared with control, bariatric surgery was associated with a significant reduction in all evaluated outcomes, including all-cause mortality (HR:0.57, 95%CI:0.51-0.65), MACE (HR:0.54, 95%CI:0.45-0.64), cardiovascular mortality, heart failure hospitalization, myocardial infarction, and stroke. Incretin receptor agonists were also associated with lower all-cause mortality (HR:0.62, 95%CI:0.52-0.74), lower MACE (HR:0.75, 95%CI:0.61-0.92) and reduced heart failure hospitalization. All-cause mortality-representing the most direct and clinically relevant endpoint-did not differ significantly between the two strategies in the exploratory network meta-analysis. Importantly, the network estimates should be cautiously interpreted, given the predominance of observational evidence, substantial heterogeneity, and very low confidence across all comparisons. Bariatric surgery and incretin receptor agonists are associated with substantial reductions in major cardiovascular outcomes in adults with obesity. In head-to-head comparisons, no significant differences were observed in all-cause mortality and stroke. Both strategies provide clinically meaningful benefits.
中文摘要:减重手术和药理学减重疗法可改善心血管代谢危险因素。然而,直接比较其对心血管结局影响的头对头研究仍然有限。我们进行了一项探索性荟萃分析,以比较肥胖成人的主要临床结局中减重手术与药理学减重疗法的差异。通过PubMed和Scopus数据库进行系统文献检索。纳入随机研究和观察性研究,比较减重手术或肠促胰蛋白受体激动剂与对照组的疗效。主要结局指标为全因死亡率和主要不良心血管事件(MACE)。采用频率学随机效应网络荟萃分析在三个节点上进行。共纳入40项研究,涉及超过190万患者。与对照组相比,减重手术与所有评估结局的显著降低相关,包括全因死亡率(HR:0.57, 95%CI:0.51-0.65)、MACE(HR:0.54, 95%CI:0.45-0.64)、心血管死亡率、心力衰竭住院、心肌梗死和中风。肠促胰蛋白受体激动剂也与较低的全因死亡率(HR:0.62, 95%CI:0.52-0.74)、较低的MACE(HR:0.75, 95%CI:0.61-0.92)以及减少的心力衰竭住院相关。在探索性网络荟萃分析中,代表最直接且临床相关终点的全因死亡率在两种策略间无显著差异。重要的是,鉴于观察性证据占主导地位、异质性较大以及所有比较的置信度极低,应对网络估计值谨慎解读。减重手术和肠促胰蛋白受体激动剂与肥胖成人主要心血管结局的大幅降低相关。在头对头比较中,全因死亡率和中风未观察到显著差异。两种策略均提供具有临床意义的益处。